Arvinas Holding Company (ARVN) AI Stock Analysis

• Market Cap: $859.32M
• Dividend Yield: N/A
• Average Volume (3M): 649.97K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.15
• Revenue Growth: N/A
• EPS Growth: N/A
• Country: US
• Employees: 430
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.48
• Shares Outstanding: 64,224,300
• 10 Day Avg. Volume: 671,458
• 30 Day Avg. Volume: 649,970
• PEG Ratio: 0.12
• Price to Book (P/B): 2.45
• Price to Sales (P/S): 5.23
• P/FCF Ratio: -5.28
• Enterprise Value/Market Cap: 1.04
• Enterprise Value/Revenue: 2.85
• Enterprise Value/Gross Profit: 2.85
• Enterprise Value/Ebitda: -10.12
• 1Y Price Target: $15.43
• Price Target Upside: 15.32% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 9
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 61 Neutral
• Price Target: $14.00 ▲(4.63% Upside)

Arvinas' overall stock score is driven by its strong technical momentum and positive corporate events, which are tempered by financial challenges and valuation concerns. The promising clinical pipeline and strategic collaborations provide a positive outlook, but ongoing financial and operational challenges remain significant.

Positive Factors

Strong Pipeline Progress

The advancement of multiple clinical programs, including ARV-102 and ARV-806, indicates robust R&D capabilities and potential for future growth.

Financial Stability

A strong cash position ensures operational stability and supports ongoing R&D efforts, enabling the company to sustain its strategic initiatives.

Strategic Collaborations

Partnerships with major pharmaceutical companies like Pfizer enhance resource access and market reach, strengthening Arvinas' competitive position.

Negative Factors

Revenue Decline

A significant revenue drop due to the end of a major agreement highlights dependency on partnerships and potential volatility in financial performance.

Cash Flow Challenges

Ongoing cash flow issues may limit the company's ability to invest in R&D and other strategic initiatives, impacting long-term growth potential.

Delayed Efficacy in Trials

Challenges in achieving desired efficacy in clinical trials could delay product development timelines and affect future revenue streams.

Arvinas Holding Company Business Overview & Revenue Model

Company Description

Arvinas, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. Its lead product candidates include Bavdegalutamide, a proteolysis targeting chimera (PROTAC) protein degrader that is in phase I clinical trial targeting the androgen receptor (AR) protein for the treatment of men with metastatic castration-resistant prostate cancer (mCRPC); ARV-471, a PROTAC protein degrader targeting the estrogen receptor protein for the treatment of patients with metastatic ER positive/HER2 negative breast cancer; and ARV-766 an investigational orally bioavailable PROTAC protein degrader for the treatment of men with mCRPC. The company has collaborations with Pfizer Inc., Genentech, Inc., F. Hoffman-La Roche Ltd., and Bayer AG. Arvinas, Inc. was founded in 2013 and is based in New Haven, Connecticut.

How the Company Makes Money

Arvinas generates revenue primarily through collaborations and partnerships with pharmaceutical companies, which may include upfront payments, milestone payments, and royalties on future product sales. The company engages in strategic alliances to co-develop its drug candidates, which allows it to share the financial burden of research and development while also gaining access to additional resources and expertise. Additionally, Arvinas may receive funding from government grants and other non-dilutive sources to support its research initiatives. As its clinical programs advance and potentially lead to new drug approvals, the company aims to monetize these assets through commercialization efforts or further partnerships.

Arvinas Holding Company Financial Statement Overview

Summary

Arvinas is facing significant financial challenges with declining revenue growth and persistent losses impacting profitability. The balance sheet shows low leverage, which is positive, but the negative return on equity and cash flow issues highlight ongoing difficulties.

Income Statement

Arvinas Holding Company has experienced a decline in revenue growth, with a negative growth rate of -16.23% in the TTM period. The company is facing challenges in profitability, as indicated by negative net profit and EBIT margins. Despite a positive gross profit margin, the overall financial performance is impacted by high operating losses.

Balance Sheet

The company maintains a low debt-to-equity ratio of 0.016, indicating low leverage and financial stability. However, the return on equity is negative, reflecting ongoing losses and challenges in generating shareholder value. The equity ratio is not explicitly calculated, but the company's equity position appears stable relative to its assets.

Cash Flow

Arvinas is experiencing negative free cash flow growth and a high operating cash flow to net income ratio, indicating cash flow challenges. The free cash flow to net income ratio is slightly above 1, suggesting that cash flow is closely aligned with net income, albeit both are negative.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	312.30M	263.40M	78.50M	131.40M	53.60M	25.90M
Gross Profit	312.30M	263.40M	78.50M	131.40M	53.60M	25.90M
EBITDA	-88.00M	-243.60M	-394.80M	-255.00M	-182.40M	-117.60M
Net Income	-58.50M	-198.90M	-367.30M	-282.50M	-191.00M	-119.30M
Balance Sheet
Total Assets	844.30M	1.09B	1.30B	1.27B	1.58B	717.40M
Cash, Cash Equivalents and Short-Term Investments	787.60M	1.04B	1.26B	1.21B	1.50B	688.60M
Total Debt	9.50M	9.70M	3.20M	5.50M	5.00M	4.10M
Total Liabilities	279.90M	529.70M	644.60M	703.90M	799.90M	75.20M
Stockholders Equity	564.40M	561.70M	660.00M	564.90M	781.70M	642.20M
Cash Flow
Free Cash Flow	-329.50M	-261.10M	-350.70M	-280.30M	554.70M	-96.20M
Operating Cash Flow	-327.50M	-259.30M	-347.80M	-273.50M	559.40M	-89.76M
Investing Cash Flow	360.70M	34.70M	203.50M	242.80M	-1.31B	164.25M
Financing Cash Flow	-16.90M	7.90M	374.70M	4.70M	278.60M	504.67M

Arvinas Holding Company Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 13.38
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ARVN, the sentiment is Positive. The current price of 13.38 is above the 20-day moving average (MA) of 12.44, above the 50-day MA of 12.28, and above the 200-day MA of 9.11, indicating a bullish trend. The MACD of 0.37 indicates Negative momentum. The RSI at 61.80 is Neutral, neither overbought nor oversold. The STOCH value of 74.60 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for ARVN.

Arvinas Holding Company Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
ARVN	61 Neutral	$859.32M	-16.66	―	―	―	―
CMPX	58 Neutral	$1.14B	-13.99	-37.82%	―	-100.00%	-28.79%
OLMA	56 Neutral	$2.02B	-14.19	-59.22%	―	―	17.23%
BCAX	56 Neutral	$920.34M	-7.53	-26.64%	―	―	-103.95%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
ANAB	49 Neutral	$1.31B	-16.82	-308.02%	―	196.42%	53.92%
MGTX	47 Neutral	$612.54M	-3.60	-611.42%	―	96.83%	-61.92%

Arvinas Holding Company Corporate Events

Arvinas Reveals Promising Preclinical Data for ARV-393

On December 6, 2025, Arvinas, Inc. announced preclinical data for ARV-393, a PROTAC BCL6 degrader, in combination with glofitamab, a CD20×CD3 bispecific antibody, at the 67th American Society of Hematology Annual Meeting. The data demonstrated that the combination significantly enhanced tumor growth inhibition and increased tumor regression rates in a high-grade B-cell lymphoma model compared to either agent alone. These findings suggest mechanistic synergies between ARV-393 and T-cell engagement, supporting the initiation of a Phase 1 clinical trial in 2026 to explore this combination as a chemotherapy-free treatment for diffuse large B-cell lymphoma.

The most recent analyst rating on (ARVN) stock is a Hold with a $13.50 price target. To see the full list of analyst forecasts on Arvinas Holding Company stock, see the ARVN Stock Forecast page.